Chinese Academy of Medical Sciences COVID-19 vaccine

Chinese Academy of Medical Sciences COVID-19 vaccine
Vaccine description
TargetSARS-CoV-2
Vaccine typeInactivated
Clinical data
Other namesCovidful (Chinese: 科维福; pinyin: Kēwéifú)
Routes of
administration		Intramuscular
Legal status
Legal status
  • Emergency authorization: China [1]
Identifiers
DrugBank

Chinese Academy of Medical Sciences COVID-19 vaccine, or IMBCAMS COVID-19 vaccine, traded as Covidful (Chinese: 科维福; pinyin: Kēwéifú), is a COVID-19 vaccine developed by Institute of Medical Biology, Chinese Academy of Medical Sciences.

Clinical trials

In May 2020, Covidful started phase I/II clinical trial with 942 participants in China.[2]

In January 2021, Covidful started phase III clinical trials with 34,020 from Brazil and Malaysia.[3]

Authorizations

  Full authorization
  Emergency authorization
  Allowed for travel

On 9 June 2021, The vaccine has been approved by the Chinese authorities.[1]

References

  1. 1 2 Liu R, Woo R (9 June 2021). "China builds new plant for IMBCAMS COVID-19 vaccine -state media". Reuters. Retrieved 15 June 2021.
  2. ↑ Clinical trial number NCT04412538 for "Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19" at ClinicalTrials.gov
  3. ↑ Clinical trial number NCT04659239 for "The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19" at ClinicalTrials.gov
This article is issued from Wmcloud. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.